In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms

The FDA has denied ITM Isotopes Techn | The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.